Literature DB >> 21476949

Immediate release of ibuprofen from Fujicalin®-based fast-dissolving self-emulsifying tablets.

Myung Joo Kang1, Soo Young Jung, Woo Heon Song, Jun Sang Park, Sung-Up Choi, Kyung Taek Oh, Hyung-Kyoon Choi, Young Wook Choi, Jaehwi Lee, Beom-Jin Lee, Sang-Cheol Chi.   

Abstract

BACKGROUND: Drug release from a solid form of self-emulsifying drug delivery system (SEDDS) has greatly been limited due to strong adsorption and physical interaction with carriers. To facilitate drug release process in the stomach, an acid-soluble powderizing carrier, Fujicalin(®) was evaluated together with different disintegrants and hydrophilic lubricants.
METHOD: Immediate-release self-emulsifying tablets (IR-SETs) of ibuprofen (IBU) was prepared with solidified SEDDS of IBU, various disintegrants, and lubricants, and drug release was evaluated to develop IR-SET that can release IBU with a similar IBU release rate to that obtained with liquid SEDDS.
RESULTS: The liquid SEDDS consisted of Capryol 90, Cremophor EL, Labrasol, and IBU at a ratio of 3:4:3:3, and was solidified with various adsorbents. The powderized SEDDS was tabletted by a direct compression. Fujicalin(®)-based SEDDS tablets demonstrated remarkably higher dissolution rate of IBU compared with Neusilin(®) and Neosyl(®)-based SEDDS tablets. The IR-SET formula of IBU prepared with Fujicalin(®) as an adsorbent, Polyplasdone(®) as a disintegrant, and sodium bicarbonate as a co-disintegrant showed over 90% of initially loaded dose of IBU released within 5 min in a stimulated gastric juice (pH 1.2), exhibiting almost equivalent rate of IBU release to that shown by liquid SEDDS. The particle size analysis revealed no significant differences in droplet sizes of the microemulsions formed from liquid (116 nm) and IR-SET (110 nm).
CONCLUSION: The novel IR-SET can be promising as a fast-releasing SEDDS tablet of IBU for fast onset of action.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21476949     DOI: 10.3109/03639045.2011.571695

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  7 in total

Review 1.  Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance.

Authors:  Angel Tan; Shasha Rao; Clive A Prestidge
Journal:  Pharm Res       Date:  2013-06-18       Impact factor: 4.200

2.  First in man bioavailability and tolerability studies of a silica-lipid hybrid (Lipoceramic) formulation: a Phase I study with ibuprofen.

Authors:  Angel Tan; Nasrin Ghouchi Eskandar; Shasha Rao; Clive A Prestidge
Journal:  Drug Deliv Transl Res       Date:  2014-06       Impact factor: 4.617

Review 3.  Current Status of Supersaturable Self-Emulsifying Drug Delivery Systems.

Authors:  Heejun Park; Eun-Sol Ha; Min-Soo Kim
Journal:  Pharmaceutics       Date:  2020-04-16       Impact factor: 6.321

4.  Development of Solid SEDDS, V: Compaction and Drug Release Properties of Tablets Prepared by Adsorbing Lipid-Based Formulations onto Neusilin® US2.

Authors:  Suhas G Gumaste; Damon M Dalrymple; Abu T M Serajuddin
Journal:  Pharm Res       Date:  2013-06-25       Impact factor: 4.200

5.  Gastroretentive Sustained-Release Tablets Combined with a Solid Self-Micro-Emulsifying Drug Delivery System Adsorbed onto Fujicalin®.

Authors:  Yoshihiro Omachi
Journal:  AAPS PharmSciTech       Date:  2022-06-08       Impact factor: 3.246

6.  Development of a Solid Supersaturable Micelle of Revaprazan for Improved Dissolution and Oral Bioavailability Using Box-Behnken Design.

Authors:  Yoon Tae Goo; Cheol-Ki Sa; Ji Yeh Choi; Min Song Kim; Chang Hyun Kim; Hyeon Kyun Kim; Young Wook Choi
Journal:  Int J Nanomedicine       Date:  2021-02-17

7.  Preformulation studies on solid self-emulsifying systems in powder form containing magnesium aluminometasilicate as porous carrier.

Authors:  Anna Krupa; Jakub Szlęk; Benedykt R Jany; Renata Jachowicz
Journal:  AAPS PharmSciTech       Date:  2014-12-11       Impact factor: 3.246

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.